Cortellis

Alzheimer’s disease – the disease without cure or prevention

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered from Clarivate Analytics Cortellis.   The unmet need The new year has seen major setbacks […]

Notable mergers & acquisitions in the life sciences in Q3 2017

During the third quarter of 2017, Cortellis Deals Intelligence had 122 deals added as part of its ongoing coverage of life science mergers & acquisitions (M&A) compared to 145 in Q2 this year and 124 in Q3 the previous year.   Deal activity in the third quarter from 2009 to 2017 Deal activity in the […]

Notable licensing deals in the biopharma industry in Q3 2017

Introduction During the third quarter of 2017, Cortellis Competitive Intelligence registered 949 new deals (excluding mergers & acquisitions) added as part of its ongoing coverage of pharmaceutical licensing activity compared to 1,007 in Q2 this year and 1,023 in Q3 the previous year. High-value deals: potentially worth $0.5 billion or more Approximately 40 high-value new […]

The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Poly ADP-ribose polymerase (PARP) inhibitors have created much excitement in the medical community since the demonstration in 2005 of the extreme sensitivity […]

Cortellis Deals Landscape Q4 2016

During the 4th quarter of 2016, Cortellis Competitive Intelligence had 889 new deals added as part of its ongoing coverage of pharmaceutical licensing activity.

Alzheimer’s disease: One year later

Alzheimer’s disease (AD) affects more than 35 million people worldwide and is the sixth-leading cause of death in the US, where its care costs are predicted to rise from $200 billion in 2012 to $1.1 trillion by 2050. The disease is the only one of the top-ten leading causes of death in the US that […]